The best bets in the sector
Jun 18, 2021
2 minutes
Two years ago my colleague Dr Mike Tubbs tipped . Since then, the share price has soared by 280%, thanks to growing interest from other drug companies (such as Janssen Biotech and ONO Pharmaceutical) in its cancer treatments involving genetically modified iPSCs. Fate has no fewer than seven iPSC-derived treatments undergoing trials,
You’re reading a preview, subscribe to read more.
Start your free 30 days